IDH2 and neoplasm: Not only can these clones be statistically explained with allele dropout, but they also do not fit with a model of serial mutation acquisition predicted by the presence of the NRAS, ASXL1, and IDH2 triple-mutant clone comprising 64% of the tumor at this time point.